SAGIMET BIOSCIENCES INC.

Analyst Reco. Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq Other stock markets 23:00:00 22/05/2024 BST			5-day change	1st Jan Change
4.7 ^USD	-7.48%		+1.73%	-13.28%

05-16	Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	MT
05-15	Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	05-16	MT
HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target	05-02	MT
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating	03-26	MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target	03-25	MT
JMP Securities Adjusts Price Target on Sagimet Biosciences to $46 From $47, Maintains Market Outperform Rating	02-07	MT
Goldman Sachs Raises Price Target on Sagimet Biosciences to $37 From $30, Keeps Buy Rating	01-23	MT
JMP Securities Raises Price Target on Sagimet Biosciences to $47 From $31, Maintains Market Outperform Rating	01-23	MT
TD Cowen Initiates Sagimet Biosciences With Outperform Rating	08/08/23	MT
Goldman Sachs Initiates Sagimet Biosciences at Buy With $33 Price Target	08/08/23	MT
Piper Sandler Initiates Sagimet Biosciences With Overweight Rating, $67 Price Target	08/08/23	MT
JMP Securities Starts Sagimet Biosciences With Market Outperform Rating, $30 Price Target	08/08/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer